Colleen Vaccaro, PA
Physician Assistant · Williamsville, NYNPI 1801987284
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by UCB, Inc. at 29.7% of the total. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,252 payments — averaging $171.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$64K
- AbbVie$41K
- Regeneron Healthcare Solutions, Inc.$27K
- Sanofi$24K
- Incyte Corporation$18K
- Amgen$13K
- plus $29K from 22 others
Across 4 payments — averaging $662.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$3K
What the payments were for
- Consulting fees$36,86717%
- Speaking & faculty fees$121,47556%
- Travel & lodging$32,08715%
- Food & beverage$24,40911%
- Education$4090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 221 | $63,932 |
| AbbVie | 247 | $41,124 |
| Regeneron Healthcare Solutions, Inc. | 94 | $27,148 |
| Sanofi | 66 | $23,831 |
| Incyte Corporation | 60 | $17,781 |
| Amgen | 39 | $12,655 |
| E.r. Squibb & Sons, L.L.C. | 64 | $5,642 |
| Janssen Scientific Affairs, LLC | 11 | $5,087 |
| Johnson & Johnson | 73 | $4,354 |
| Galderma Laboratories, L.p. | 20 | $3,737 |
| Novartis | 139 | $3,311 |
| Sun Pharmaceutical Industries Inc. | 42 | $1,988 |
| Dermavant Sciences, Inc. | 57 | $1,764 |
| Lilly USA, LLC | 44 | $865 |
| Pfizer | 37 | $759 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $519 |
| Arcutis Biotherapeutics, Inc. | 13 | $139 |
| LEO Pharma Inc. | 4 | $103 |
| Organon | 4 | $87 |
| Bristol Myers Squibb | 1 | $80 |
| Sanofi-aventis U.S. LLC | 1 | $69 |
| Boehringer Ingelheim | 3 | $68 |
| Sandoz | 2 | $59 |
| Paratek Pharmaceuticals, Inc. | 3 | $54 |
| Nabriva Therapeutics, PLC | 2 | $39 |
| Biofrontera Inc. | 1 | $22 |
| Botanix SB Inc | 1 | $14 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$215,246 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 69 | $301,657 |
| OtezlaApremilast | 38 | $193,233 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 19 | $143,231 |
| Dupixent SyringeDupilumab | 23 | $116,944 |
| Taltz AutoinjectorIxekizumab | 13 | $89,547 |
| AdbryTralokinumab-Ldrm | 12 | $46,163 |
| VtamaTapinarof | 17 | $21,229 |
| Tacrolimus | 52 | $6,780 |
| Doxycycline Ir-DrDoxycycline Monohydrate | 13 | $6,538 |
| Tretinoin | 55 | $4,125 |
| Halobetasol Propionate | 70 | $4,071 |
| Azelaic Acid | 19 | $3,961 |
| Ivermectin | 14 | $3,576 |
| Clobetasol Propionate | 92 | $2,940 |
| Doxycycline Hyclate | 123 | $2,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $12,655 | $193,23338 claims |
| LEO Pharma Inc.Adbry | $103 | $46,16312 claims |
| Dermavant Sciences, Inc.Vtama | $1,764 | $21,22917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Williamsville
- Henry YuBronx$1M
- Michael AsbachAmherst$962K
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
- Melissa WhiteGarden City$320K
- Lawrence HermanHolbrook$315K
- Kaitlyn NelsonBrooklyn$289K
- Sari KatzGarden City$271K
- Julius NwosuBronx$256K
- Cameron KiserNew York$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.